Alzheimer's disease: current and future therapeutic perspectives.
1. A better understanding of the pathophysiology of AD has been made possible through population-based epidemiological studies, human genetic and post-mortem studies, leading to a number of testable hypothesis towards delaying progression. 2. A number of disease milestones have been identified as therapeutic targets, such as conversion from MCI to diagnosable dementia. 3. Clinicians caring for patients with AD have currently available a number of symptomatic drugs, and will have in the future the ability to predict the risk for asymptomatic individuals to develop AD, and provide advice towards prevention.
McGill Centre for Studies in Aging, Montreal, Canada.
S
S
Gauthier
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000503:physiopathology* / Q000523:psychology; D018678:Cholinergic Agents / Q000494:pharmacology; D002800:Cholinesterase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003071:Cognition; D018450:Disease Progression; D006801:Humans
D018678:Cholinergic Agents; D002800:Cholinesterase Inhibitors